FanaMental Pharma is developing neuroprotective small molecules for the treatment of currently untreatable human neurological conditions.
Industry
Sector :
Subsector :
Keywords :
Company Type
For Profit
Last funding type
Seed
IPO status
Private
Description
The company has laid the foundation for the development of FMP neuroprotectiva, which have an entirely new pharmacological mode of action and are expected to be broadly applicable in the treatment of conditions such as vascular brain damage, dementia, traumatic brain injury, ALS, AD, HD, retina degeneration, and brain damage caused by virus or parasite infections.
